Ambit Biosciences prices IPO at $8

By
A A A

Ambit Biosciences, which is developing small molecule therapeutics for the treatment of acute myeloid leukemia, raised $65 million by offering 8.1 million shares at $8. Ambit Biosciences plans to list on the NASDAQ under the symbol AMBI. Ambit Biosciences initially filed confidentially on 12/20/2012. Citi and Leerink Swann acted as joint bookrunners on the deal.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: AMBI

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

My Career No Longer Exists
My Career No Longer Exists          

Stocks

Referenced

Most Active by Volume

21,888,227
    $23.02 unch
9,438,405
  • $30.69 ▼ 5.66%
8,410,019
  • $45.2602 ▼ 2.25%
7,307,537
  • $15.48 ▼ 0.64%
6,039,612
  • $5.8549 ▼ 15.15%
5,537,693
    $19.75 unch
5,400,955
  • $97.07 ▼ 1.10%
4,916,119
  • $2.56 ▲ 8.47%
As of 7/31/2014, 09:51 AM